Treatment of pediatric plasma cell myeloma type post‐transplant lymphoproliferative disorder with modern risk‐directed therapy

Post‐transplant lymphoproliferative disorder (PTLD) related plasma cell neoplasms are rare in pediatric patients. We report a pediatric liver transplant recipient with plasma cell myeloma type PTLD. Cytogenetics included 1q duplication, associated with poor prognosis in adult multiple myeloma, and t(8;14). High‐risk cytogenetics has not been reported in pediatric plasma cell myeloma type PTLD. The patient was treated with bortezomib, dexamethasone, and lenalidomide with subsequent autologous stem cell transplant. He achieved a 6‐year remission, demonstrating tolerance to and efficacy of this modern myeloma regimen in a pediatric patient. Unfortunately, he subsequently died from complications of repeat liver transplant.

[1]  G. Salles,et al.  Array‐CGH predicts prognosis in plasma cell post‐transplantation lymphoproliferative disorders , 2017, Genes, chromosomes & cancer.

[2]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[3]  A. S. Kim,et al.  Plasmacytoma-like Posttransplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Recipient , 2016, Journal of pediatric hematology/oncology.

[4]  Wenming Chen,et al.  Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma , 2014, Oncology letters.

[5]  陈文明,et al.  Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma , 2015 .

[6]  S. Lonial,et al.  Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients , 2014, Leukemia.

[7]  J. Said,et al.  Plasmacytoma‐like post‐transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients , 2013, Pediatric blood & cancer.

[8]  R. Fonseca,et al.  Myeloma: classification and risk assessment. , 2013, Seminars in oncology.

[9]  G. Mazariegos,et al.  Decreasing Incidence of Symptomatic Epstein‐Barr Virus Disease and Posttransplant Lymphoproliferative Disorder in Pediatric Liver Transplant Recipients: Report of the Studies of Pediatric Liver Transplantation Experience , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  W. Sanger,et al.  Early onset, EBV(-) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. , 2013, Blood.

[11]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[12]  A. Dipchand,et al.  A 16‐Year Multi‐Institutional Study of the Role of Age and EBV Status on PTLD Incidence Among Pediatric Heart Transplant Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[14]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[15]  R. Mahfouz,et al.  Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. , 2009, Leukemia research.

[16]  Jian-yong Li,et al.  Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14). , 2009, Leukemia research.

[17]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[18]  T. Hall,et al.  Post‐transplant multiple myeloma in a pediatric renal transplant patient , 2006, Pediatric blood & cancer.

[19]  B. Barlogie,et al.  Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q , 2005, Genes, chromosomes & cancer.

[20]  V. Dharnidharka,et al.  Post‐Transplant Lymphoproliferative Disorder in the United States: Young Caucasian Males are at Highest Risk , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  B. Barlogie,et al.  Plasma cell karyotype in multiple myeloma. , 1988, Blood.